| |
| Issue |
Title |
| |
| No 4 (2024) |
Clinical and economic aspects of chronic cerebral ischemia treatment |
Abstract
PDF (Rus)
|
|
A. V. Kiselev, A. L. Khokhlov, S. V. Stovbun, S. A. Speshilova, E. G. Lileeva |
| |
| No 4 (2024) |
Clinical-economic assessment of the potential contribution of evogliptin to achieving the targets of the Federal project «Fight against diabetes mellitus» and reduction of population mortality |
Abstract
PDF (Rus)
|
|
N. N. Avxentyev, A. S. Makarov, I. A. Karpova, V. V. Yavlyanskaya |
| |
| No 2 (2023) |
Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis |
Abstract
PDF (Rus)
|
|
S. K. Zyryanov, I. N. Dyakov, N. I. Ilina |
| |
| No 1 (2023) |
Application of the cost-effectiveness method in improving the pharmacotherapy of multiple myeloma |
Abstract
PDF (Rus)
|
|
E. A. Luchinin, M. V. Zhuravleva, T. V. Shelekhova, V. S. Bogova, E. V. Luchinina |
| |
| No 4 (2022) |
Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy |
| |
| No 4 (2022) |
Comparative pharmacoeconomic analysis of the use of apixaban, rivaroxaban and dabigatran for prevention of stroke and embolism in the vessels of the systemic circulation in patients with non-valvular atrial fibrillation |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, A. R. Kasimova, S. R. Gilyarevskiy |
| |
| No 1 (2022) |
Clinical-economic analysis of the target therapy in severe atopic dermatitidis in adults |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, Y. M. Gomon, M. A. Proskurin, Y. E. Balikina |
| |
| No 1 (2022) |
Mirabegron: pharmacoeconomic aspects of the use of the drug for the treatment of overactive bladder syndrome |
Abstract
PDF (Rus)
|
|
O. I. Ivakhnenko, E. V. Derkach, V. S. Krysanova, A. D. Ermolaeva, K. A. Kokushkin |
| |
| No 1 (2022) |
The clinical-economic characteristic of current basis-bolus insulin therapy schemes in diabetes mellitus type 1 in adults |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, A. A. Kurilev, Y. E. Balikina, M. A. Proskurin |
| |
| No 4 (2021) |
The economic side of an oral sugar lowering therapy intensification by glucagon-like peptidt-1 receptor agonists |
Abstract
PDF (Rus)
|
|
S. K. Zyryanov, I. N. Dyakov |
| |
| No 3 (2021) |
Clinical and economic justification of screening for mucopolysaccharidosis type I in children at groups of risks |
Abstract
PDF (Rus)
|
|
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova |
| |
| No 3 (2021) |
A social-economic burden of rhinosinusitis with nasal polyps with comorbid asthma and influence of dupilumab |
Abstract
PDF (Rus)
|
|
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova |
| |
| No 2 (2021) |
Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base |
Abstract
PDF (Rus)
|
|
I. N. Dyakov, S. K. Zyryanov |
| |
| No 2 (2021) |
COVID-19: economic aspects of influenza vaccine prevention |
Abstract
PDF (Rus)
|
|
E. A. Zhidkova, E. M. Gutor, Yu. A. Tkachenko, I. V. Rogova, I. A. Popova, K. G. Gurevich |
| |
| No 2 (2021) |
Individualized prophylactic treatment of patients with hemophilia A to improve effectiveness and optimize product consumption on the example of octocog alpha and rurioctocog alpha pegol. A systematic literature review |
Abstract
PDF (Rus)
|
|
A. G. Tolkushin, M. E. Holownia-Voloskova, N. L. Pogudina |
| |
| No 1 (2021) |
Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base |
Abstract
PDF (Rus)
|
|
I. N. Dyakov, S. K. Zyryanov |
| |
| No 1 (2021) |
Pharmacoeconomic analysis of the choice of antimicrobial drugs for the treatment of community-acquired pneumonia by physicians and final year medical students |
Abstract
PDF (Rus)
|
|
V. G. Deriushkin, S. V. Gatsura |
| |
| No 1 (2021) |
Socioeconomic and global burden of COVID-19 |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, Yu. M. Gomon, Yu. E. Balykina, D. Yu. Belousov, V. V. Strizheletskiy, I. G. Ivanov |
| |
| No 1 (2021) |
Pharmacoeconomic feasibility of using Mirabegron in patients with overactive bladder |
Abstract
PDF (Rus)
|
|
I. N. Dyakov, G. R. Kasyan |
| |
| No 5 (2020) |
Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin |
| |
| No 5 (2020) |
Clinical-economic evaluation of a screening for Pompe disease in children in the local conditions |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, I. A. Vilum, Yu. E. Balikina, M. A. Proskurin, O. I. Karpov |
| |
| No 5 (2020) |
Cystic fibrosis as a social-economic burden |
Abstract
PDF (Rus)
|
|
A. S. Kolbin, Yu. M. Gomon, O. I. Karpov, Yu. E. Balykina, M. A. Proskurin |
| |
| No 5 (2020) |
The pharmacoeconomic comparison of the fixed insulin glargine and lixisenatide combination with insulin degludec family in type 2 diabetes mellitus |
Abstract
PDF (Rus)
|
|
I. N. Dyakov, S. K. Zyryanov |
| |
| No 5 (2020) |
Th e clinical-economic analysis of Dupilumab in severe asthma |
Abstract
PDF (Rus)
|
|
I. S. Krysanov, V. S. Krysanova, V. Yu. Ermakova |
| |
| 1 - 24 of 194 Items |
1 2 3 4 5 6 7 8 9 > >>
|
